SyntekaBio, Inc.
Financials
Valuation Metrics
SyntekaBio, Inc.'s Market Cap is ₩277B. At end of 2025 it was ₩945B. Ranked #2149 of 2,421 in KR market (top 89%), #1392 of 1,640 on KOSDAQ (top 85%), #88 of 96 in Health Care Equipment & Services (top 92%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 27.65B KRW | KR#2,149/2,421 Sec#88/96 |
| Revenue | 3.09B KRW | KR#2,369/2,421 Sec#94/96 |
| Net Income | -11.96B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 37.98B KRW | KR#2,295/2,421 Sec#83/96 |
| Net Assets | 25.93B KRW | KR#2,217/2,421 Sec#81/96 |
| Employees | 61 | KR#1,960/2,421 Sec#82/96 |
| Value | ||
| P/B | 1.07x | KR#1,521/2,421 Sec#46/96 |
| P/S | 8.96x | KR#2,261/2,421 Sec#83/96 |
| FCF Yield | -38.55% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | -46.12% | KR#2,268/2,421 Sec#84/96 |
| ROA | -31.48% | KR#2,326/2,421 Sec#88/96 |
| Op. Margin | -339.67% | KR#2,353/2,421 Sec#91/96 |
| Revenue Growth | 132.30% | KR#63/2,421 Sec#5/96 |
| Financial Health | ||
| Debt Ratio | 46.49% | KR#916/2,421 Sec#50/96 |
| Total Debt | 6.36B KRW | KR#1,744/2,421 Sec#61/96 |
| FCF | -10.66B KRW | KR#1,724/2,421 Sec#64/96 |
| Cash | 7.46B KRW | KR#1,848/2,421 Sec#62/96 |
| Current Ratio | 0.97x | KR#1,755/2,421 Sec#79/96 |
| Performance | ||
| 1Y Return | -68.96% | KR#2,291/2,421 Sec#90/96 |
| 1M Return | 8.57% | KR#539/2,421 Sec#13/96 |
| From 52W High | -83.11% | KR#2,368/2,421 Sec#93/96 |
| 1Y MDD | -82.20% | KR#2,329/2,421 Sec#90/96 |
| Trading | ||
| Volume | 255,062 shares | KR#404/2,421 Sec#14/96 |
| Trading Value | 294.3M KRW | KR#1,132/2,421 Sec#40/96 |
| Foreign Own. | 1.00% | KR#2,039/2,421 Sec#80/96 |
| Per Share | ||
| EPS | -493 KRW | KR—/2,421 Sec—/96 |
| BPS | 1,069 KRW | KR#2,291/2,421 Sec#86/96 |
Company Info
Syntekabio, a bio venture established in 2009, became a research institute company in 2014, receiving dedicated supercomputing technology for genetic testing from ETRI. It offers AI new drug development platform services and a genomic big data platform, including NGS-ARS® precision medicine services, on a cloud basis. Leveraging an AI platform that integrates supercomputing and genomic big data technologies, Syntekabio focuses on innovating the new drug development process and developing new paradigm treatments. The company is headquartered in Yuseong-gu, Daejeon Metropolitan City.